Around 1.5 million Australians suffer from sleep disorders with majority of them facing sleep apnoea. Of all the sleep disorders, the Obstructive Sleep Apnoea (OSA) is the most common and potentially serious disorder where breathing repeatedly stops and starts with an association to snoring.
But the Brisbane-based medical device company, Oventus Medical Limited (ASX: OVN) has developed a unique treatment platform for such sleep disorders. It has designed oral devices using the unique and patented technology for airflow that enables unobstructed mouth breathing while maintaining an oral seal and stable jaw position.
The clinical studies have shown that partial blockage of the airway during sleep often leads to a severe sleep disorder, Obstructive Sleep Apnoea, that usually goes unnoticed among people. It causes disruptive sleep, memory impairment, and other emotional slumps in daytime functioning, affecting around 17% of women and 34% of men. This calls for critical attention to the massively growing Obstructive Sleep Apnoea (OSA) market, as tapped by Oventus.
The ASX-listed health care company, Oventus has addressed this escalating medical problem with the range of branded sleep treatment products including the recently launched O2Vent® Optima oral device. The device incorporates proprietary Oventus Airway Technology that advances the jaw forward to open the airway and improve the effectiveness of oral appliance therapy. Besides supplementing breathing through airways, it allows nasal breathing if the nose is unobstructed.
As per the company’s information, O2Vent® Optima offers a strong alternative to Continuous positive airway pressure (CPAP) therapy which is many times refused by patients. Further, it reportedly has an added advantage of the lower price on the back of reduced material costs and reduced manufacturing times achieved by the company. Oventus’ O2Vent® Optima was launched in Canada on 4 February 2019 and is due to be launched in the United States in mid-year 2019.
Oventus’ second discovery includes a valve product ExVent™ that reportedly integrates with its select O2Vent® devices to reduce airway collapsibility and normalize ventilation. The company has confirmed that by inserting this valve into the ‘duck bill’ of Oventus’ O2Vent™ device improves efficacy for those patients who need more intervention. ExVentTM is reportedly expected to be released in Australia during Q1CY2019.
Along with ExVent™ valve, O2Vent ONEPAP™ valve and O2Vent Connect™ CPAP connection are the two more discoveries by Oventus in collaboration with CSIRO and Neuroscience Research Australia in the Federal Government-funded project. In integration with Oventus’ O2Vent™ device, O2Vent ONEPAP™ valve will reportedly act as a mini CPAP valve without the need for cords or power and O2Vent Connect™ CPAP connection would enable CPAP at lower pressures, without the need for a full face mask.
The company stated that these product discoveries represent the biggest improvements in sleep medicine in decades. And it can be seen that these innovations have gained traction from investors as the Oventus’ stock price increased by 6.90% over the past three years.
Today, 13 February, OVN is trading at $0.315, up by 1.613% as at 2:28 PM AEST.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.